Treats severe alopecia areata. Sold as Leqselvi. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Deuruxolitinib phosphate (sold as Leqselvi), first approved Jul 25, 2024, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 25, 2024 | LeqselviNDA 217900 · New molecular entity | Sun Pharmaceutical Industries | 1 | Marketed |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Leqselvi | Part D | $165K | New | 20 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA